ClinConnect ClinConnect Logo
Search / Trial NCT04363684

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

Launched by MAYO CLINIC · Apr 24, 2020

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

ClinConnect Summary

The ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) trial is a large research study focused on understanding various forms of Frontotemporal Lobar Degeneration (FTLD) and related conditions, such as Progressive Supranuclear Palsy (PSP) and different types of Primary Progressive Aphasia. The goal is to learn more about how these diseases progress over time and how they affect individuals, which can help improve diagnosis and treatment options in the future.

To participate, individuals must be between the ages of 65 and 74 and either have a family history of FTLD or show symptoms of the disease without a known family history. Participants will undergo regular check-ups and assessments to monitor their condition, and they may also provide blood samples for further research. It’s important to note that individuals with certain other medical conditions or brain injuries will not be eligible for the study. This trial aims to gather valuable information that can lead to better understanding and care for those affected by FTLD.

Gender

ALL

Eligibility criteria

  • Longitudinal Arm Inclusion Criteria
  • Familial FTLD (f-FTLD) participants (either is acceptable):
  • members of families in whom at least one member has a known disease-associated mutation in one of the major genes that cause f-FTLD: MAPT, GRN, C9orf72 (or other rare genes)
  • an autosomal dominant family history of a FTLD syndrome (without a known gene) verified by medical record review or well-documented family history including family members with a medical history consistent with FTLD or a related disorder.
  • Sporadic FTLD (s-FTLD) participants:
  • Sporadic participants should be symptomatic with no known family history nor a genetic mutation indicating f-FTLD. All sporadic participants must have an FTLD syndrome as a referring diagnosis; those determined by ALLFTD clinicians to have non-FTLD diagnoses will be excluded from longitudinal visits, but their baseline visit will be included in comparative datasets. For inclusion in the longitudinal follow-up, participants should meet research criteria for one of the following FTLD syndromes:
  • Progressive Supranuclear Palsy (PSP)
  • Semantic variant Primary Progressive Aphasia (svPPA)
  • Nonfluent variant Primary Progressive Aphasia (nfvPPA)
  • Corticobasal Degeneration (CBD)/Corticobasal Syndrome (CBS)
  • Behavioral variant Frontotemporal dementia (bvFTD)
  • Frontotemporal Dementia with Amyotrophic Lateral Sclerosis (FTD/ALS)
  • Biofluid-Focused Arm Inclusion Criteria
  • Participants enrolled in the biofluid arm may be either f-FTLD or s-FTLD. All general inclusion criteria apply. Participants should meet research criteria (as specified above) for any FTLD syndrome or meet familial FTLD inclusion criteria. Because the biofluid arm participants do not undergo the same detailed clinical and functional assessments required for the longitudinal arm, participants may be included regardless of primary language, as long as an appropriately translated consent is available.
  • Exclusion Criteria:
  • Known presence of a structural brain lesion (e.g. tumor, cortical infarct) that could reasonably explain symptoms in a symptomatic participant.
  • Known presence of an Alzheimer's disease causing mutation in PSEN1, PSEN2 or APP; or biomarker evidence for Alzheimer's disease as a cause of the clinical syndrome.
  • A previous history of Korsakoff encephalopathy, severe alcohol dependence (within 5 years of onset of dementia), frequent alcohol or other substance intoxication, or other neurological disorder.
  • Evidence through history or laboratory testing of uncorrected B12 deficiency (B12 \< 95% of local laboratory's normal value), unregulated hypothyroidism (TSH \>150% of normal), HIV positive, renal failure (creatinine \> 2), liver failure (ALT or AST \> two times normal), respiratory failure that requires supplemental oxygen, large confluent white matter lesions, significant systemic medical illnesses such as deteriorating cardiovascular disease.
  • Current medication likely to affect CNS functions in the opinion of the site PI.
  • In the site investigator's opinion, the participant cannot complete sufficient key study procedures. The participant may be enrolled into the biofluid-focused arm if they can tolerate a blood draw and short clinical exam, but must be able to complete at least 75% of study procedures for enrollment into the longitudinal arm.

About Mayo Clinic

Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.

Locations

Chicago, Illinois, United States

Ann Arbor, Michigan, United States

Boston, Massachusetts, United States

Philadelphia, Pennsylvania, United States

New York, New York, United States

San Diego, California, United States

Seattle, Washington, United States

Los Angeles, California, United States

Baltimore, Maryland, United States

Rochester, Minnesota, United States

Atlanta, Georgia, United States

Indianapolis, Indiana, United States

Chapel Hill, North Carolina, United States

Vancouver, British Columbia, Canada

Toronto, Ontario, Canada

Jacksonville, Florida, United States

Birmingham, Alabama, United States

Nashville, Tennessee, United States

Las Vegas, Nevada, United States

New York, New York, United States

Denver, Colorado, United States

San Francisco, California, United States

Saint Louis, Missouri, United States

New York, New York, United States

Cleveland, Ohio, United States

Houston, Texas, United States

Bethesda, Maryland, United States

San Antonio, Texas, United States

New York City, New York, United States

Patients applied

0 patients applied

Trial Officials

Bradley Boeve, MD

Principal Investigator

Mayo Clinic

Adam Boxer, MD, PhD

Principal Investigator

University of California, San Francisco

Howie Rosen, MD

Principal Investigator

University of California, San Francisco

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials